Sumary of Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progression:
- “While it is deemed low or inconclusive whether DAA therapy helps prevent HCC recurrence, little is known about how the antiviral therapy affects progression of the liver disease after cancer treatment.
- To account for bias inherent in a single-center retrospective study, a multivariate adjusted time-varying Cox regression analysis showed a 72% reduction in tumor progression in the DAA-treated group and an 88% reduction in risk of death from HCC.
- Our study showed that eliminating the hepatitis C virus with DAA suppresses tumor progression, which we suggest contributes to overall patient survival.
- ” Hiroko Ikenaga, First Author HCV infection affects 71 million people worldwide and accounts for about 65% of the causes of liver cancer in Japan.